

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Currently Amended). A method for ~~enhancing functional neuronal recovery in an individual suffering from secondary neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition that has caused primary neuronal damage in the central nervous system (CNS) or peripheral nervous system (PNS) of that individual, or in an individual having neurodegeneration caused or exacerbated by glutamate toxicity, or in an individual having a psychosis or psychiatric disorder selected from the group consisting of an anxiety disorder, a mood disorder, schizophrenia or a schizophrenia-related disorder, drug use and dependence and withdrawal, and a memory loss or cognitive disorder,~~ down-regulating the suppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> Treg cells at the site of a lesion in the central or peripheral nervous system, comprising administering to the individual a subject in need, an amount of poly-Glu,Tyr effective to enhance functional neuronal recovery in the individual down-regulate the suppressive activity of CD4<sup>+</sup>CD25<sup>+</sup> Treg cells at the lesion site and thereby boost the immune response at the lesion site and cause effector T cells, which

recognize their antigen at the lesion site, to home there and activate the resident cells to eliminate self-destructive compounds that cause nerve degeneration and to secrete growth factors that may induce axonal elongation, synaptogenesis and neurogenesis..

2 (Currently Amended). ~~A~~The method in accordance with claim 1, wherein the ~~individual~~ subject in need is one suffering from ~~secondary neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition that has caused a primary neuronal damage lesion in the CNS or PNS of that individual, and wherein said administering step comprises administering poly-Glu,Tyr in an amount effective to reduce the secondary neurodegeneration at the site.~~

3. (Currently Amended). ~~A~~The method in accordance with claim 2, wherein the ~~individual~~ subject in need is one suffering from an injury that has caused a primary neuronal damage lesion.

4 (Currently Amended). ~~A~~The method in accordance with claim 3, wherein said injury is selected from the group consisting of spinal cord injury, closed head injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, cerebral ischemia, optic nerve injury and injury caused by tumor excision.

5 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 4, wherein said injury is spinal cord injury.

6 (Currently Amended). ~~A~~The method in accordance with claim 4, wherein said injury is ischemic stroke.

7 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 2, wherein said injury, disease, disorder or condition is a neurodegenerative disease, disorder or condition associated with the eye.

8 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 7, wherein said neurodegenerative disease, disorder or condition associated with the eye is non-arteritic optic neuropathy or a disease associated with elevated intraocular pressure.

9 (Cancelled).

10 (Currently Amended). ~~A~~The method in accordance with claim 1, wherein the ~~individual~~ subject in need is one having neurodegeneration at a lesion caused or exacerbated by glutamate toxicity, ~~and wherein said administering step comprises administering poly-Glu,Tyr to the individual in an amount effective to ameliorate the neurodegeneration caused or exacerbated by glutamate toxicity.~~

11 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 10, wherein the ~~neurodegeneration~~ lesion

caused or exacerbated by glutamate toxicity is associated with a neurodegenerative disease, disorder or condition.

12 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 11, wherein said neurodegenerative disease, disorder or condition is selected from the group consisting of senile dementia, Parkinson's disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis (ALS), and Creutzfeldt-Jakob disease.

13 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 10, wherein the ~~neurodegeneration~~lesion caused or exacerbated by glutamate toxicity is associated with a peripheral neuropathy.

14 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 13, wherein said peripheral neuropathy is selected from the group consisting of adrenomyeloneuropathy, amyloid polyneuropathy, chronic ataxic neuropathy, diabetic neuropathy, carpal tunnel syndrome, intervertebral disc herniation, giant axonal neuropathy, ischemia, vitamin deficiency, malabsorption syndromes, alcoholism, a toxic neuropathy caused by organophosphates, a neuropathy associated with a disease or disorder selected from the group consisting of ataxia telangiectasia, Charcot-Marie-Tooth disease, obstructive lung diseases, Fabry's disease,

Friedreich ataxia, hypoglycemia, IgG or IgA gammopathies, lipoproteinemia, Refsum's syndrome, and Sjogren-Larsson syndrome, or a polyneuropathy associated with various drugs or with hypoglycemia.

15 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 10, wherein the ~~neurodegeneration-lesion~~ caused or exacerbated by glutamate toxicity is associated with epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, or opiate tolerance and dependence.

16 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 1, wherein the ~~individual-subject in need~~ is one having a psychosis or psychiatric disorder selected from the group consisting of an anxiety disorder, a mood disorder, schizophrenia or a schizophrenia-related disorder, drug use and dependence and withdrawal, and a memory loss or cognitive disorder.

17 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 16, wherein said psychosis or psychiatric disorder is an anxiety disorder selected from the group consisting of a phobic disorder, an obsessive-compulsive disorder, a post-traumatic stress disorder, an acute stress disorder and a generalized anxiety disorder; said mood disorder is selected from the group consisting of depression, a dysthymic disorder, a bipolar disorder and a cyclothymic

disorder; said schizophrenia-related disorder is selected from the group consisting of brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder; said drug use and dependence is selected from the group consisting of alcoholism, opiate dependence, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use; and said memory loss disorder is amnesia or memory loss associated with a disease or disorder selected from the group consisting of Alzheimer's type dementia, non-Alzheimer's type dementia, Parkinson's disease, Huntington's disease, Creutzfeld-Jakob disease, head trauma, HIV infection, hypothyroidism and vitamin B12 deficiency.

18 (Currently Amended/Withdrawn). ~~A~~The method in accordance with claim 16, wherein said psychosis or psychiatric disorder is schizophrenia.

19 - 72 (Cancelled).